The estimated Net Worth of Matthew Strobeck is at least 115 百万$ dollars as of 21 May 2024. Matthew Strobeck owns over 347,840 units of QuidelOrtho stock worth over 115,303,923$ and over the last 12 years he sold QDEL stock worth over 0$. In addition, he makes 184,917$ as Independent Director at QuidelOrtho.
Sign up
Matthew Strobeck QDEL stock SEC Form 4 insiders trading
Matthew has made over 22 trades of the QuidelOrtho stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 347,840 units of QDEL stock worth 15,600,624$ on 21 May 2024.
The largest trade he's ever made was buying 2,669,562 units of QuidelOrtho stock on 21 November 2022 worth over 3,069,996$. On average, Matthew trades about 80,253 units every 60 days since 2013. As of 21 May 2024 he still owns at least 2,570,879 units of QuidelOrtho stock.
You can see the complete history of Matthew Strobeck stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Strobeck biography
Dr. Matthew W. Strobeck is Independent Director of the Company. Dr. Strobeck is currently the Managing Partner of Birchview Capital. Dr. Strobeck was a Partner and Member of the Management Committee and Advisory Board of Westfield Capital Management from 2008 until 2011, having served as a member of the investment team, specializing in healthcare and life sciences, from May 2003 to June 2008. Dr. Strobeck currently serves on the Boards of Accelerate Diagnostics, a medical diagnostics company; Tepha Inc., a medical device company; Biodesix, a private diagnostic company; and Monteris Medical, a medical device company. Dr. Strobeck received his B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, a S.M. from the Harvard University/MIT Health Sciences Technology Program, and an S.M. from the MIT Sloan School of Management.
What is the salary of Matthew Strobeck?
As the Independent Director of QuidelOrtho, the total compensation of Matthew Strobeck at QuidelOrtho is 184,917$. There are 17 executives at QuidelOrtho getting paid more, with Douglas Bryant having the highest compensation of 4,168,770$.
How old is Matthew Strobeck?
Matthew Strobeck is 47, he's been the Independent Director of QuidelOrtho since 2018. There are 26 older and 1 younger executives at QuidelOrtho. The oldest executive at QuidelOrtho Corporation is Mary Polan, 76, who is the Independent Director.
What's Matthew Strobeck's mailing address?
Matthew's mailing address filed with the SEC is 9975 SUMMERS RIDGE ROAD, , SAN DIEGO, CA, 92121.
Insiders trading at QuidelOrtho
Over the last 21 years, insiders at QuidelOrtho have traded over 509,235,797$ worth of QuidelOrtho stock and bought 304,015 units worth 10,385,234$ . The most active insiders traders include Jack W Schuler、Matthew Strobeck、Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of 1,246,606$. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth 3,078,785$.
What does QuidelOrtho do?
QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.
What does QuidelOrtho's logo look like?
Complete history of Matthew Strobeck stock trades at Accelerate Diagnostics Inc、QuidelOrtho、Biodesix Inc
QuidelOrtho executives and stock owners
QuidelOrtho executives and other stock owners filed with the SEC include:
-
Douglas Bryant,
President, Chief Executive Officer, Director -
Douglas C. Bryant,
Pres, CEO & Director -
Randall Steward,
Chief Financial Officer -
Michael Abney,
Senior Vice President - Distribution -
Robert Bujarski,
Chief Operating Officer -
Ratan Borkar,
Senior Vice President - International Commercial Operations -
Werner Kroll,
Senior Vice President - R&D -
Edward Russell,
Senior Vice President - Business Development -
Robert J. Bujarski,
Chief Operating Officer -
Randall J. Steward,
Chief Financial Officer -
Dr. Werner Kroll,
Sr. VP of R&D -
Ratan S. Borkar,
Sr. VP of International Commercial Operations -
Robert J. Bujarski J.D.,
Pres & COO -
Kenneth Buechler,
Independent Chairman of the Board -
Edward Michael,
Independent Director -
Ken Widder,
Independent Director -
Charles Slacik,
Independent Director -
Matthew Strobeck,
Independent Director -
Mary Polan,
Independent Director -
Kathy Ordonez,
Independent Director -
Ruben Argueta,
Director - Investor Relations -
Ann Rhoads,
Director -
Karen Gibson,
Senior Vice President, Information Systems and Business Transformation -
Dr. Chockalingam Palaniappan Ph.D.,
Chief Innovation Officer -
Patrick E. Klein,
Chief Admin. Officer -
Louise Brandy,
Chief Information Officer -
Rhys de Callier,
VP of Strategy & Portfolio Management -
Dr. Johannes Kehle,
Pres of AnDiaTec Division -
Phillip S. Askim,
VP, Associate Gen. Counsel & Sec. -
Michael S. Iskra,
Chief Commercial Officer -
Joseph M. Busky CPA,
Chief Financial Officer -
Karen C. Gibson,
Sr. VP of Digital Health Bus. Unit -
Edward Keith Russell,
Sr. VP of Bus. Devel. -
Michael Donald Abney Jr.,
Sr. VP of North American Sales & Distribution -
Michelle A. Hodges,
Sr. VP & Gen. Counsel -
Group Inc.Carlyle Holdings ...,
-
Thomas D Brown,
Director -
Rodney F Dammeyer,
Director -
John Tamerius,
Sr. VP - Clinical/Reg Affairs -
Patrick Klein,
Chief Administrative Officer -
Louise Brandy,
SVP, Chief Information Officer -
Tamara A. Ranalli,
SVP, Molecular Bus. Unit -
Mark W Smits,
SVP-Commercial Operations -
Mark Pulido,
Director -
John Matthew Radak,
Chief Financial Officer -
Timothy Todd Stenzel,
Chief Science Officer -
Scot M Mc Leod,
Sr. VP - Operations -
Caren L Mason,
President and CEO -
Jack W Schuler,
Director -
Thomas James Foley,
Chief Technical Officer -
David R. Scholl,
Senior Vice President -
Richard C Iii Tarbox,
Sr. VP - Corporate Development -
Matthew T Heindel,
Sr. VP - Global Sales & Mrktg -
Douglas S Harrington,
Director -
Faye Wattleton,
Director -
Mark Paiz,
Senior Vice President -
Thomas A Glaze,
Director -
Paul E Landers,
Sr. V.P., CFO and Secretary -
S Wayne Kay,
President & CEO -
William J. Ferenczy,
SVP, Cardio/Metabolic Unit -
Michael S. Iskra,
EVP & CCO -
Christopher M Smith,
Director -
Joseph D Jr. Wilkins,
-
Evelyn S Dilsaver,
-
Joseph M Busky,
Chief Financial Officer -
James Prutow,
-
Michelle A. Hodges,
SVP, General Counsel